Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting
Authors:
- Digisha TrivediDTDigisha Trivedi
- Min YouMYMin You
- Lisa RosenblattLRLisa Rosenblatt
- 25 February 2014
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 17 (4) , 259-265
Abstract
This study examined total healthcare costs and rates of patients with rheumatoid arthritis (RA) who switch biologic disease-modifying anti-rheumatic drug (bDMARD) therapy in a real world setting. A retrospective longitudinal analysis was conducted in patients with RA using IMS PharMetrics Plus database from 1/1/2004 to 3/31/2010. The first-line cohort included patients newly initiated on abatacept or the tumor necrosis factor-alpha inhibitors (anti-TNFs) adalimumab, etanercept, or infliximab, with 12 months of continuous follow-up. The second-line cohort included patients initiating a bDMARD with evidence of a different bDMARD within the previous 2 years and with 12 months of continuous follow-up. Switching was defined as a different bDMARD claim within a 200% gap in days supply from the previous bDMARD claim. Non-switchers stayed on their bDMARD in the follow-up period. Monthly total healthcare costs for switchers and non-switchers and rates of bDMARD switching were examined. Switch rates for each bDMARD were also compared. First-line switchers had significantly higher monthly total healthcare costs after the switch than non-switchers ($3759 vs $2343; p < 0.05), as did second-line switchers ($3956 vs $2616; p < 0.05). First-line abatacept (2.1%) had significantly lower rates of switching compared to adalimumab (9.5%), etanercept (9.0%), and infliximab (5.5%). Second-line abatacept (8.0%) had significantly lower rates of switching compared to adalimumab (16.7%), etanercept (14.4%), and infliximab (14.3%). There are no clinical data available in this database and, therefore, this study did not examine the clinical drivers of healthcare costs and switch rates. Monthly total healthcare costs were higher for bDMARD switchers following the switch compared to non-switchers. Patients on abatacept switched less frequently than patients on anti-TNFs. This study highlights the need to identify patients who are likely to switch in order to ensure they receive the appropriate therapy which may improve outcomes and decrease healthcare costs.Keywords
This publication has 11 references indexed in Scilit:
- Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World SettingsAdvances in Therapy, 2012
- Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohortArthritis Care & Research, 2011
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- Switching rheumatoid arthritis treatments: An updateAutoimmunity Reviews, 2011
- Therapeutic options for rheumatoid arthritisExpert Opinion on Pharmacotherapy, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Switching between anti-tumour necrosis factors: trying to get a handle on a complex issueAnnals of the Rheumatic Diseases, 2007
- Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceRheumatology, 2007
- Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort studyArthritis & Rheumatism, 2007
- Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Research & Therapy, 2006